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Summary
Purpose/Methods: The aP2 gene product (aP2 protein) is known to be expressed by preadipocytes and other immature fat
cells in vitro. A mouse monoclonal antibody raised against an 18 amino acid segment of the aP2 protein was found to react
with lipoblasts and fetal fat cells in paraffin sections of soft tissue tumours of adipose differentiation. In this immunohisto-
chemical study, we have further examined the diagnostic utility of aP2 expression in distinguishing tumours of adipose differ-
entiation from other benign and malignant soft tissue tumours.
Result and discussion aP2 was strongly expressed by lipoblasts in lipoblastomas and all types of liposarcoma as well as brown
fat cells in hibernomas. Optimal conditions for immunohistochemical identification of lipoblasts in tumours of adipose differ-
entiation was noted when the antibody was diluted 1:30 to 1:50. Small lipoblast-like fat cells in pleomorphic lipoma and
spindle cell lipoma also showed variable staining for aP2 at this dilution of the antibody. Most benign and malignant soft
tissue tumours were distinguished by their absence of staining for aP2 protein, but some cases of myxoma, malignant fibrous
histiocytoma, synovial sarcoma and leiomyosarcoma contained tumour cells which reacted for aP2. aP2 protein expression
is likely to prove a useful means of distinguishing lipoblasts in liposarcoma but it should be used as part of a tumour panel
to exclude expression in other forms of mesenchymal tumour.
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Introduction
Benign and malignant tumours of adipose differenti-
ation are amongst the most common of soft tissue
tumours.1  Morphological  identification  of  atypical
lipoblasts is essential for the diagnosis of liposarcoma
as these cells are not present in other types of malignant
soft tissue tumour. With the exception of lipoblast-
oma, and to a lesser extent pleomorphic lipoma and
spindle cell lipoma, lipoblasts are absent from benign
tumours  of  adipose  differentiation.  Morphological
identification of lipoblasts may be problematic, how-
ever, as these cells can be few in number or difficult
to identify in well-differentiated liposarcomas. They
may be also difficult to distinguish morphologically
from vacuolated tumour cells in non-adipose benign
and malignant mesenchymal soft tissue tumours.
We  have  previously  shown  that  both  polyclonal
and  monoclonal antibodies  raised  against  the  aP2
protein can be used to identify lipoblasts and fetal fat
cells in tumours of adipose differentiation immuno-
histochemically.2,3  aP2  expression  was  noted  in
liposarcomas,  lipoblastomas  and  hibernomas.  The
aP2 gene (also known as P422 and adipocyte lipid
binding protein) codes for a 132 amino acid, single
chain 14.6kd polypeptide which shows considerable
homology with myelin P2 protein.4,5 aP2 expression
is coincident with acquisition of the morphological
features  of  the  adipocyte  phenotype  4  and  aP2  is
expressed in preadipocytes late in adipogenesis.6
In this study, we have determined whether the aP2
protein is expressed in a range of benign and malig-
nant soft tissue tumours, including various types of
tumours  of  adipose  differentiation.  We  have  also
sought  to  characterise  the  optimal  conditions
required for immunohistochemical staining using the
monoclonal antibody  which  identifies this  antigen.
On this basis, we have sought to determine whether
aP2 expression can reliably be used as a marker of
lipoblasts and fetal fat cells in the diagnosis of soft
tissue lesions.
Materials and methods
The anti aP2 antibody used in this study is a non-com-
mercial monoclonal antibody raised against a synthetic
peptide corresponding to the 18 amino acid sequence
of residues 10–28 of the aP2 protein.3 The antibody
was  not  affinity  purified.  5µm  paraffin  sections  of140 T. T. Yang et al.
tumours of adipose differentiation and other benign
and malignant soft tissue tumours, retrieved from the
files  of  the  Nuffield  Orthopaedic  Centre,  were
mounted onto glass slides and immunohistochemical
screening with the aP2 antibody, used undiluted and
diluted in phosphate-buffered saline (1:5, 1:10, 1:20,
1:30, 1:40, 1:50, 1:100),  was carried out by a two-
stage  indirect  immunoperoxidase  technique  as
described previously.7 Negative controls consisted of
the addition of phosphate buffered saline instead of the
primary antibody or the use of an irrelevant antibody
of the same immunoglobulin subclass (IgG2) [anticy-
tokeratin CAM 5.2 (Becton-Dickinson Oxford UU)].
The number and range of tumours examined in
this study are shown in Table 1. Histological criteria
used for the identification of lipoblasts and for the
pathological diagnosis of soft tissue tumours (such as
malignant  fibrous  histiocytoma)  examined  in  this
study were those described in Enzinger and Weiss.1
Where  appropriate  the  various  tumours  were  also
stained immunohistochemically with monoclonal or
polyclonal antibodies directed against specific cellu-
lar antigens known to be expressed by tumour cells in
particular mesenchymal neoplasms (e.g. cytokeratin
for synovial sarcoma and epithelioid sarcoma; MIC-
2 for Ewing’s sarcoma).
Results
aP2 protein expression, as identified by immunohis-
tochemical staining, was noted in brown fat cells in
hibernomas and lipoblasts in lipoblastomas and all
types of liposarcoma (Table 1). Small fat  vacuoles
within the cytoplasm of brown fat cells in hibernomas
reacted strongly for aP2 (Figure 1); the cell mem-
brane was  also  stained but  nuclei were unstained.
Morphologically identifiable lipoblasts [i.e. univacu-
olated cells with a nucleus at one edge of the cell or
multivacuolated cells with numerous lipid droplets in
the  central  nucleus1],  as  well  as  spindle-shaped,
round and pleomorphic cells, many of which con-
tained small fat vacuoles, also stained for aP2 in well-
differentiated, myxoid, round cell and pleomorphic
liposarcomas (Figure 2).
Table 1. aP2 expression in soft tissue tumours
Soft tissue tumours
Number of cases of each 
tumour studied
Number of cases showing aP2 
reaction (dilution 1:30)
Tumours of adipose differentiation
Lipoma 12 0
Pleomorphic lipoma 3 1
Intramuscular lipoma 4 0




well differentiated 13 11
myxoid 8 6
round cell 5 5
pleomorphic 6 5
Other mesenchymal tumours
Myxoma (intramuscular) 6 1
Benign fibrous histiocytoma 2 0
Fibromatosis (extra-abdominal) 5 0
Glomus tumour 2 1
Haemangioma 2 0
Neurilemmoma 2 0
Epithelioid sarcoma 2 1
Malignant fibrous histiocytoma 6 1
Synovial sarcoma 6 0
Ewing’s tumour 6 0
Clear cell sarcoma 2 0
Rhabdomyosarcoma (embryonal) 4 0
Lelomyosarcoma 6 1
Osteosarcoma (soft tissue/bone) 4 0
Fig. 1. Indirect immunoperoxidase staining of a hibernoma 
showing staining of small fat vacuoles in brown fat cells for aP2 
(1:30 dilution) (×400 original magnification).aP2 in soft tissue tumours 141
There  was  marked  variation  in  the  extent  of
staining of lipoblasts and small fat  cells within the
various types of liposarcomas. To some degree this
depended on the  dilution of  the primary antibody
employed.  Most  lipoblasts  stained  when  the  anti-
body  was  used undiluted or  when  diluted at  1:5,
1:10 or 1:20; at these dilutions, however, antibody
staining was  not  specific and other cell and tissue
components,  including endothelial  cells  and  some
mature fat cells, also reacted for aP2. More specific
staining  of  lipoblasts  was  seen  when  the  antibody
was  used at  a  relatively  high  dilution  (1:30,  1:40
and 1:50). No staining of lipoblasts was seen when
the antibody was used at 1:100 dilution. This pat-
tern of  staining was  not  affected  by  microwave or
protease pre-treatment of sections. When used at a
dilution of  1:30,  20–50%  of  lipoblasts  in myxoid,
round  cell  and  pleomorphic  liposarcomas  reacted
for  aP2.  At this  dilution, fewer than  20%  of  lipo-
blasts reacted for aP2 in well-differentiated liposar-
comas; however, as indicated above, the proportion
of lipoblasts stained in this subtype of liposarcoma
was much increased when the antibody was used at
a lower dilution. It was noted that normal mature
subcutaneous adipose tissue and mature fat cells in
simple  lipomas  were  negative  for  aP2  when  the
antibody  was  used  at  a  high  dilution  (1:30  or
more).
A single case of pleomorphic lipoma and two cases
of spindle cell lipoma showed staining of small lipo-
blast-like  fat  cells for  aP2  when  the  antibody  was
diluted more than 1:30. It was also found that iso-
lated spindle-shaped tumour cells in some mesenchy-
mal soft tissue tumours which were not of adipose
differentiation, including cases of malignant fibrous
histiocytoma (Figure 3), synovial sarcoma, leiomyo-
sarcoma and myxoma, also reacted for aP2 when the
antibody dilution was less than 1:30 (Table 1). No
aP2 staining, however, was seen in cases of fibroma-
tosis,  benign  fibrous  histiocytoma,  epithelioid  sar-
coma,  Ewing’s  tumour,  clear  cell  sarcoma,
rhabdomyosarcoma,  and  osteosarcoma  when  the
antibody was used at this dilution.
Discussion
This study has confirmed that aP2 protein expression
is found in lipoblasts and fetal fat cells in tumours of
adipose differentiation, such as hibernoma, lipoblast-
oma  and  liposarcoma.  aP2  was  also  expressed by
lipoblast-like small fat  cells in pleomorphic lipoma
and spindle cell lipoma as well as by mesenchymal
tumour cells in some non-adipose benign and malig-
nant soft tissue tumours; this immunoreactivity was
most marked when the antibody was used at an anti-
body dilution of 1:30 or less. These findings indicate
that, although aP2 appears to be strongly expressed
by lipoblasts and immature cells of the adipocyte lin-
eage, this antigen is also expressed by some mature
fat cells, endothelial cells and non-adipose mesenchy-
mal tumour cells.
Genes regarded as early or late markers of adipocyte
differentiation code for protein products which are
associated with fat metabolism.8,9 Although many of
these proteins, including aP2, are mainly restricted to
fat cells, their expression is generally not confined to
cells of adipose differentiation.10 Thus, our finding of
aP2 expression in a few mesenchymal tumour cells
which are not of the adipocyte lineage is not too sur-
Fig. 2. Indirect immunoperoxidase staining of (a) a myxoid liposarcoma and (b) a round cell liposarcoma showing positive aP2 stain-
ing of lipoblasts for aP2 (1:30 dilution) (×400 original magnification).
Fig. 3. Indirect immunoperoxidase staining of a malignant 
fibrous histiocytoma showing positive aP2 staining of round 
and spindle-shaped tumour cells (1:10 dilution) (×250 original 
magnification).142 T. T. Yang et al.
prising. The various types of mesenchymal cells which
are  found  in  connective  tissue  tumours  are  also
thought to be derived from a common primordial stem
cell and there may be conservation of this epitope by
primitive cells present in these lesions.11 In general,
we found that mature adipose tissue and most benign
adipose tissue tumours (with the exception of hiber-
noma and lipoblastoma) were largely negative for aP2
when the antibody identifying this antigen was used
at a dilution of 1:30 or more. On this basis, aP2 expres-
sion is likely to be useful in the distinction of well-dif-
ferentiated  lipoma-like  liposarcoma  from  simple
lipoma. In general, lack of aP2 expression should also
be useful in identifying small mature fat cells in benign
adipose tissue tumours and small necrotic or degen-
erate fat cells in areas of fat necrosis or area of fibrosis
in mature fat. Although all morphological variants of
liposarcoma were found to stain for the aP2 protein,
the extent of the immunohistochemical staining of
lipoblasts was variable in terms of the number of cells
stained and the strength of the reaction. aP2 staining,
however, was noted in a few cases of spindle cell lipoma
and pleomorphic lipoma, although the  majority of
these lesions were negative for aP2; although staining
of these lesions may restrict the practical diagnostic use
of this antibody, it should be noted that lipoblast-like
cells  have  been  identified ultrastructurally  in  both
spindle cell lipoma and pleomorphic lipoma.12,13,14
aP2 expression is likely to be particularly valuable
in  tumour diagnosis as  there  are  few  specific  his-
tochemical markers of fat cell differentiation.1,15,16 It
should be particularly useful in distinguishing liposa-
rcoma  from  other  sarcomas  containing  numerous
vacuolated pleomorphic/round tumour cells such as
rhabdomyosarcoma, Ewing’s sarcoma, clear cell sar-
coma and leiomyosarcoma. It should also be useful in
the differential diagnosis of myxoid tumours of soft
tissue.17 Lipoblasts in liposarcomas showed strong
staining when the anti-aP2 antibody was used undi-
luted or diluted 1:5. 1:10 or 1.20; however, it was
found  that  use  of  this  antibody  at  this  dilution
resulted in some loss of specificity with cells other
than lipoblasts being stained. More specific staining
was seen when the antibody was used at a dilution
greater than 1:30.  As aP2  expression in malignant
tumours is generally restricted to liposarcoma when
the monoclonal antibody is used at a dilution of 1:20
or more our results suggest that at this dilution the
anti-aP2 antibody is best employed as part of an anti-
body panel to characterise the immunophenotype of
tumour cells in malignant soft tissue neoplasms.
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